Wealth Enhancement Advisory Services’s Atea Pharmaceuticals AVIR Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$58.1K	Buy	+11,266	New	+$57.6K	﹤0.01%	4025

Other funds holding AVIR

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Auour Investments Woburn, Massachusetts $353M AUM 8.66% 1-Year Est. Return

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Sunpointe St. Louis, Missouri $328M AUM 26.96% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.5B AUM 13.02% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Wealth Enhancement Advisory Services's AVIR Position: Q3 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Atea Pharmaceuticals (AVIR) in Q3 2026: 11,266 shares worth $58.1K. The stake represents ﹤0.01% of the portfolio and ranks #4025 among its holdings.

22 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.

Wealth Enhancement Advisory Services held 11,266 shares of Atea Pharmaceuticals worth $58.1K as of Q3 2026.
Atea Pharmaceuticals was a new Wealth Enhancement Advisory Services position in Q3 2026.
Atea Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #4025 holding.
22 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.